DOXYCHEL HYCLATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOXYCHEL HYCLATE (DOXYCHEL HYCLATE).
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA binding to the mRNA-ribosome complex.
| Metabolism | Partially metabolized in the liver via non-enzymatic pathways; primarily excreted unchanged in urine and feces. |
| Excretion | Doxycycline hyclate is primarily excreted via the feces (approximately 90%) as an inactive chelated complex, with renal excretion accounting for about 10% of the dose. Biliary excretion is minimal. |
| Half-life | Terminal elimination half-life is 18–22 hours in patients with normal renal function; prolonged to 20–30 hours in severe renal impairment. Clinical context: Allows once- or twice-daily dosing. |
| Protein binding | 90–93% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.75 L/kg (range 0.5–1.0 L/kg), indicating extensive tissue penetration and distribution into body fluids (e.g., pleural, ascitic, synovial). |
| Bioavailability | Oral: 90% (fasting); reduced by 20% with food or dairy. IV: 100%. |
| Onset of Action | Intravenous: Within 1 hour. Oral: 2–4 hours. Topical (gel/cream): 1–2 weeks for clinical improvement in acne. |
| Duration of Action | Duration of action is 24 hours following oral administration due to long half-life, supporting once-daily dosing. For acne, clinical improvement is noted after 2–4 weeks of topical use. |
| Molecular Weight | 512.9 |
100 mg orally or IV every 12 hours on day 1, then 100 mg daily.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR >10 mL/min; for GFR <10 mL/min, use with caution and consider dose reduction to 100 mg every 24 hours. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) and consider dose reduction. |
| Pediatric use | 8 years or older: 2.2 mg/kg every 12 hours on day 1, then 2.2 mg/kg daily; maximum 100 mg/dose. Not recommended under 8 years. |
| Geriatric use | Use with caution due to increased risk of esophageal irritation; consider starting at lower dose (e.g., 100 mg daily) and monitor renal function. |
| 1st trimester | Category D: Tetracyclines can cause fetal harm when administered to a pregnant woman. Use in the first trimester is associated with a risk of teratogenicity, including neural tube defects and cardiovascular malformations. Avoid use unless absolutely necessary. |
| 2nd trimester | Category D: Use of tetracyclines during the second trimester may cause reversible inhibition of bone growth and permanent discoloration of teeth (yellow-gray-brown) in the developing fetus. Avoid use unless no alternative exists. |
| 3rd trimester | Category D: Exposure in the third trimester can cause fetal skeletal malformations and dental staining. Contraindicated in pregnancy, especially after the first trimester, due to risk of hepatotoxicity in the mother (rare) and adverse effects on the fetus. |
Clinical note
Comprehensive clinical and safety monograph for DOXYCHEL HYCLATE (DOXYCHEL HYCLATE).
| Placental transfer | Doxycycline crosses the placenta and achieves fetal serum concentrations approximately 25-60% of maternal levels. It binds to developing bones and teeth, causing discoloration and hypoplasia. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to doxycycline or any tetracyclinePregnancy (especially second and third trimesters)Children under 8 years of age (risk of permanent tooth discoloration and bone growth inhibition)Severe hepatic impairment
| Precautions | Esophageal ulceration risk; take with adequate fluids, Photosensitivity reactions, Hepatotoxicity, especially in pregnancy or with pre-existing liver disease, Tooth discoloration and enamel hypoplasia in children <8 years, Skeletal development impairment in premature infants, Overgrowth of non-susceptible organisms including Clostridioides difficile, Intracranial hypertension (pseudotumor cerebri), Antianabolic effect leading to increased BUN, Avoid in penicillin-allergic patients with severe allergy (not contraindicated but caution), Exacerbation of systemic lupus erythematosus |
| Food/Dietary | Avoid dairy products (milk, yogurt, cheese), calcium-fortified juices, antacids, and iron supplements within 2 hours of dosing. Food does not significantly affect absorption but may reduce GI upset. |
Loading safety data…
| Breastfeeding |
| Doxycycline is excreted into human milk in low concentrations. Theoretical risk of dental staining and bone growth inhibition exists, but at typical maternal doses, the amount ingested by the infant is small and not expected to cause adverse effects. Consider using an alternative antibiotic when possible, especially for prolonged courses. American Academy of Pediatrics considers doxycycline compatible with breastfeeding. |
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | FDA Category D. First trimester: Avoid due to risk of fetal skeletal malformations and neural tube defects. Second/third trimester: Risk of permanent tooth discoloration (yellow-gray-brown) and hypoplasia of enamel; reversible inhibition of bone growth. Contraindicated after 4th month of gestation. |
| Fetal Monitoring | Monitor maternal liver function tests and renal function. Assess fetal growth and skeletal development via ultrasound if exposure occurs. In case of accidental use, dental follow-up for infant after tooth eruption. |
| Fertility Effects | No significant effect on fertility reported in human studies. Animal studies show no impairment. Doxycycline may transiently alter vaginal flora but does not impair gametogenesis. |
| Clinical Pearls | Doxycycline hyclate is a tetracycline antibiotic with high oral bioavailability; absorption is decreased by dairy products, antacids, and iron supplements. It is photosensitizing; advise sun avoidance and sunscreen use. It can cause esophageal irritation; take with full glass of water and remain upright for 30 minutes. Avoid in children under 8 and during pregnancy due to tooth discoloration and bone growth inhibition. Consider in patients with renal impairment as it is primarily hepatically excreted. |
| Patient Advice | Take with a full glass of water and remain upright for 30 minutes to prevent esophageal irritation. · Avoid dairy products, antacids, iron supplements, and calcium-rich foods within 2 hours of taking this medication. · Use sunscreen and protective clothing to prevent severe sunburn reaction. · Complete the full course even if you feel better. · Not for use in children under 8 years or during pregnancy/lactation. |